DE602005007215D1 - Kleinmolekülige hemmer für mrp1 und andere multiarzneimitteltransporter - Google Patents

Kleinmolekülige hemmer für mrp1 und andere multiarzneimitteltransporter

Info

Publication number
DE602005007215D1
DE602005007215D1 DE602005007215T DE602005007215T DE602005007215D1 DE 602005007215 D1 DE602005007215 D1 DE 602005007215D1 DE 602005007215 T DE602005007215 T DE 602005007215T DE 602005007215 T DE602005007215 T DE 602005007215T DE 602005007215 D1 DE602005007215 D1 DE 602005007215D1
Authority
DE
Germany
Prior art keywords
mrp1
hemmer
transporters
medicinal
small molecular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005007215T
Other languages
English (en)
Inventor
Michelle Haber
Murray Norris
Andrei Gudkov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Cancer Institute Australia for Medical Research
Cleveland Clinic Foundation
Original Assignee
University of New South Wales
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of New South Wales , Cleveland Clinic Foundation filed Critical University of New South Wales
Publication of DE602005007215D1 publication Critical patent/DE602005007215D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE602005007215T 2004-05-14 2005-05-13 Kleinmolekülige hemmer für mrp1 und andere multiarzneimitteltransporter Active DE602005007215D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57114904P 2004-05-14 2004-05-14
PCT/US2005/016832 WO2005113004A2 (en) 2004-05-14 2005-05-13 Small molecule inhibitors for mrp1 and other multidrug transporters

Publications (1)

Publication Number Publication Date
DE602005007215D1 true DE602005007215D1 (de) 2008-07-10

Family

ID=34969673

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005007215T Active DE602005007215D1 (de) 2004-05-14 2005-05-13 Kleinmolekülige hemmer für mrp1 und andere multiarzneimitteltransporter

Country Status (7)

Country Link
US (1) US8318724B2 (de)
EP (1) EP1753422B1 (de)
AT (1) ATE396725T1 (de)
AU (1) AU2005244872B2 (de)
DE (1) DE602005007215D1 (de)
NZ (1) NZ551424A (de)
WO (1) WO2005113004A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102088852A (zh) * 2008-07-10 2011-06-08 南方研究所 5-喹啉酮和咪唑并嘧啶化合物和其用途
RS63320B1 (sr) 2010-12-08 2022-07-29 The U S A As Represented By The Secretary Department Of Health And Human Services Supstituisani pirazolopirimidini kao aktivatori glukocerebrozidaze
KR101629540B1 (ko) * 2013-02-25 2016-06-13 중앙대학교 산학협력단 신규 벤조 이미다조 이미다졸 유도체 및 이를 유효성분으로 함유하는 피부 미백용 조성물
EA201790995A1 (ru) 2014-11-06 2017-10-31 Лизосомел Терапьютикс Инк. ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
MX2018012207A (es) 2016-04-06 2019-03-28 Lysosomal Therapeutics Inc Compuestos de pirrol[1,2-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos.
JP7046827B2 (ja) 2016-04-06 2022-04-04 リソソーマル・セラピューティクス・インコーポレイテッド イミダゾ［１，５－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用
EP3440080A4 (de) * 2016-04-06 2020-01-22 Lysosomal Therapeutics Inc. Pyrazolo[1,5-a]pyrimidinyl-carboxamid-verbindungen und deren verwendung in der behandlung von medizinischen störungen
BR112018072552A8 (pt) 2016-05-05 2023-03-14 Lysosomal Therapeutics Inc Compostos de imidazo [1,2-b]piridazinas e imidazo [1,5-b] piridazinas substituídas, composição farmacêutica que os compreende e seu uso no tratamento de distúrbios médicos

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2126636T3 (es) * 1992-05-19 1999-04-01 Adir Derivados del bencimidazol con actividad antidiabetica y antiagregante plaquetaria.
AU693791B2 (en) * 1994-05-12 1998-07-09 Orsolya Csuka Compounds for reversing drug resistance
WO1999051236A1 (en) * 1998-04-08 1999-10-14 Eli Lilly And Company Methods for inhibiting mrp1
CA2404665A1 (en) * 2000-03-30 2001-10-11 The Penn State Research Foundation Novel compounds for enhancing chemotherapy
AU2002254342A1 (en) * 2001-03-23 2002-10-08 The Board Of Trustees Of The University Of Illinois Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same

Also Published As

Publication number Publication date
US8318724B2 (en) 2012-11-27
AU2005244872B2 (en) 2008-09-11
US20080032966A1 (en) 2008-02-07
AU2005244872A1 (en) 2005-12-01
ATE396725T1 (de) 2008-06-15
EP1753422A2 (de) 2007-02-21
WO2005113004A3 (en) 2006-02-09
EP1753422B1 (de) 2008-05-28
NZ551424A (en) 2009-10-30
WO2005113004A2 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
DE602005007215D1 (de) Kleinmolekülige hemmer für mrp1 und andere multiarzneimitteltransporter
Tran et al. Survival comparison between glioblastoma multiforme and other incurable cancers
Zhang et al. Targeting WD repeat domain 5 enhances chemosensitivity and inhibits proliferation and programmed death-ligand 1 expression in bladder cancer
Chabner et al. Chemotherapy and the war on cancer
Rapozzi et al. Anticancer activity of cationic porphyrins in melanoma tumour-bearing mice and mechanistic in vitro studies
Milano et al. The proteasome: a worthwhile target for the treatment of solid tumours?
DE602004017194D1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
NO20073211L (no) Tibulinbindende anti-cancerstoffer og promedikamenter av disse
BRPI0415525A (pt) derivados de imidazola e seu uso como agentes farmacêuticos
TW200633704A (en) N-substituted benzimidazolyl c-kit inhibitors and combinatorial benzimidazole library
MY148688A (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
BRPI0519243A2 (pt) mÉtodos e composiÇÕes para tratar doenÇas relacionadas a amilàide
WO2005013800A3 (en) Elevated hedgehog pathway activity in digestive system tumors, and methods of treating digestive system tumors having elevated hedgehog pathway activity
MY149169A (en) Method of treating cancer with a vegf antagonist and an anti-proliferative agent
EA201000900A1 (ru) Ингибиторы кинезина в качестве средств для лечения рака
EA201100136A1 (ru) 2,4'-бипиридинилы в качестве ингибиторов протеинкиназы d, применимые для лечения сердечной недостаточности и рака
CY1110889T1 (el) C-αρυλο γλυκοζιτικοι sglt2 αναστολεις και μεθοδος για την παραγωγη τους
EA200701808A1 (ru) Производные тетрагидроиндолона и тетрагидроиндазолона
WO2007048002A3 (en) Camptothecin derivatives as chemoradiosensitizing agents
WO2009156735A3 (en) New therapeutic agents
SE0401342D0 (sv) Therapeutic compounds
WO2007053574A3 (en) Combinations comprising sorafenib and interferon for the treatment of cancer
CY1109607T1 (el) Παραγωγο εποθιλονης για τη θεραπευτικη αντιμετωπιση του ηπατωματος και αλλων κακοηθων νοσων
Negi et al. Transient rRNA synthesis inhibition with CX-5461 is sufficient to elicit growth arrest and cell death in acute lymphoblastic leukemia cells
EA201070085A1 (ru) Потенцирование химиотерапии рака

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: THE CLEVELAND CLINIC FOUNDATION, CLEVELAND, OH, US

Owner name: CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDI, AU

8364 No opposition during term of opposition